Charles River Laboratories | CRL - Cash And Equivalent

Stock Price
150.85
Daily Change
-8.27 -5.20%
Monthly
-14.75%
Yearly
7.01%
Q2 Forecast
147.82

Charles River Laboratories reported $191.83M in Cash and Equivalent for its fiscal quarter ending in March of 2026.





Cash And Equivalent Change Date
Agilent USD 1.76B 31M Dec/2025
Align Technology USD 1.06B 35.07M Mar/2026
Bio-Rad Laboratories USD 507.2M 22.6M Mar/2026
Bruker USD 133.4M 165.4M Mar/2026
Cardinal Health USD 3.94B 1.16B Mar/2026
Charles River Laboratories USD 191.83M 21.94M Mar/2026
Cigna USD 7.04B 636M Mar/2026
Concord Medical Services Hldg CNY 243.38M 85.1M Jun/2023
CVS Health USD 9.54B 1.09B Mar/2026
Danaher USD 5.7B 1.09B Mar/2026
Dentsply International USD 190M 136M Mar/2026
Elevance Health USD 9.66B 166M Mar/2026
Humana USD 4.95B 751M Mar/2026
Illumina USD 1.42B 368M Dec/2025
Incyte USD 4.02B 435.22M Mar/2026
Intrexon USD 9.34M 1.77M Jun/2024
IQVIA Holdings USD 1.95B 33M Mar/2026
Laboratory Of America USD 981.1M 448.8M Mar/2026
Lakefront Biotherapeutics EUR 66.8M 21.06M Mar/2026
Lonza CHF 719M 188M Dec/2025
McKesson USD 3.98B 1.02B Mar/2026
Merck EUR 2.33B 77M Dec/2025
Mettler Toledo International USD 66.89M 2.18M Dec/2025
Novartis USD 6.88B 4.56B Mar/2026
Pfizer USD 1.7B 561M Mar/2026
Quest Diagnostics USD 393M 27M Mar/2026
Revvity USD 860.32M 59.54M Mar/2026
Thermo Fisher Scientific USD 3.25B 6.6B Mar/2026
United Therapeutics USD 1.28B 277.4M Mar/2026
UnitedHealth USD 31.23B 3.11B Mar/2026
Veradigm USD 492.6M 7.57M Sep/2022
Waters USD 462M 125.83M Mar/2026
West Pharmaceutical Services USD 521.4M 269.9M Mar/2026